Mammalian target of rapamycin as a target in hematological malignancies

被引：15
作者：
Kelly, Kevin R. [1 ]
Rowe, Julie H. [1 ]
Padmanabhan, Swaminathan [1 ]
Nawrocki, Steffan T. [1 ]
Carew, Jennifer S. [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
TARGETED ONCOLOGY | 2011年 / 6卷 / 01期
关键词：
mTOR; Hematological malignancies; Novel agents; Targeted therapy; ACUTE MYELOID-LEUKEMIA; MANTLE CELL LYMPHOMA; SINGLE-AGENT TEMSIROLIMUS; PHASE-II TRIAL; EVERY; WEEKS; MULTIPLE-MYELOMA; IN-VIVO; INHIBITOR EVEROLIMUS; PHOSPHOINOSITIDE; 3-KINASE; DEFOROLIMUS AP23573;
D O I：
10.1007/s11523-011-0175-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.
引用
收藏
页码：53 / 61
页数：9
相关论文
共 50 条
  • [21] Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
    Xu, Da-zhi
    Geng, Qi-rong
    Tian, Ying
    Cai, Mu-yan
    Fang, Xin-juan
    Zhan, You-qing
    Zhou, Zhi-wei
    Li, Wei
    Chen, Ying-bo
    Sun, Xiao-wei
    Guan, Yuan-xiang
    Li, Yuan-fang
    Lin, Tong-yu
    BMC CANCER, 2010, 10
  • [22] Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment
    LoRusso, Patricia Mucci
    ONCOLOGY, 2013, 84 (01) : 43 - 56
  • [23] Targeted Inhibition of Mammalian Target of Rapamycin for the Treatment of Advanced Renal Cell Carcinoma
    Kapoor, Anil
    Figlin, Robert A.
    CANCER, 2009, 115 (16) : 3618 - 3630
  • [24] Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis
    Huber, S.
    Bruns, C. J.
    Schmid, G.
    Hermann, P. C.
    Conrad, C.
    Niess, H.
    Huss, R.
    Graeb, C.
    Jauch, K-W
    Heeschen, C.
    Guba, M.
    KIDNEY INTERNATIONAL, 2007, 71 (08) : 771 - 777
  • [25] Dissecting Mammalian Target of Rapamycin to Promote Longevity
    Mendelsohn, Andrew R.
    Larrick, James W.
    REJUVENATION RESEARCH, 2012, 15 (03) : 334 - 337
  • [26] MAMMALIAN TARGET OF RAPAMYCIN IN INFLAMMATORY SKIN CONDITIONS
    Balato, A.
    Di Caprio, R.
    Lembo, S.
    Mattii, M.
    Megna, M.
    Schiattarella, M.
    Tarantino, G.
    Balato, N.
    Ayala, F.
    Monfrecola, G.
    EUROPEAN JOURNAL OF INFLAMMATION, 2014, 12 (02) : 341 - 350
  • [27] Targeting the Mammalian Target of Rapamycin in Lung Cancer
    Vicary, Glenn W.
    Roman, Jesse
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2016, 352 (05) : 507 - 516
  • [28] Ferulic Acid Induces Mammalian Target of Rapamycin Inactivation in Cultured Mammalian Cells
    Bian, Zehua
    Furuya, Norihiko
    Zheng, Dong-Mei
    Trejo, Juan Alejandro Oliva
    Tada, Norihiro
    Ezaki, Junji
    Ueno, Takashi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (01) : 120 - 124
  • [29] Myxoid liposarcoma and the mammalian target of rapamycin pathway
    Sanfilippo, Roberta
    Dei Tos, Angelo P.
    Casali, Paolo G.
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (04) : 379 - 383
  • [30] Current and future directions in mammalian target of rapamycin inhibitors development
    Fasolo, Angelica
    Sessa, Cristiana
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (03) : 381 - 394
12345